JP2019507180A - がんに対する組合せ療法 - Google Patents

がんに対する組合せ療法 Download PDF

Info

Publication number
JP2019507180A
JP2019507180A JP2018546596A JP2018546596A JP2019507180A JP 2019507180 A JP2019507180 A JP 2019507180A JP 2018546596 A JP2018546596 A JP 2018546596A JP 2018546596 A JP2018546596 A JP 2018546596A JP 2019507180 A JP2019507180 A JP 2019507180A
Authority
JP
Japan
Prior art keywords
seq
checkpoint
cells
ido
immunotherapeutic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018546596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507180A5 (enExample
Inventor
アンデルセン，マッズ，ハルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1603805.1A external-priority patent/GB201603805D0/en
Priority claimed from GBGB1610018.2A external-priority patent/GB201610018D0/en
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Publication of JP2019507180A publication Critical patent/JP2019507180A/ja
Publication of JP2019507180A5 publication Critical patent/JP2019507180A5/ja
Priority to JP2022027569A priority Critical patent/JP7417645B2/ja
Priority to JP2024000506A priority patent/JP7785817B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018546596A 2016-03-04 2017-03-03 がんに対する組合せ療法 Pending JP2019507180A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022027569A JP7417645B2 (ja) 2016-03-04 2022-02-25 がんに対する組合せ療法
JP2024000506A JP7785817B2 (ja) 2016-03-04 2024-01-05 がんに対する組合せ療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1603805.1 2016-03-04
GBGB1603805.1A GB201603805D0 (en) 2016-03-04 2016-03-04 Combination
GBGB1610018.2A GB201610018D0 (en) 2016-06-08 2016-06-08 Combination
GB1610018.2 2016-06-08
PCT/EP2017/055093 WO2017149150A1 (en) 2016-03-04 2017-03-03 Combination therapy against cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022027569A Division JP7417645B2 (ja) 2016-03-04 2022-02-25 がんに対する組合せ療法

Publications (2)

Publication Number Publication Date
JP2019507180A true JP2019507180A (ja) 2019-03-14
JP2019507180A5 JP2019507180A5 (enExample) 2020-04-09

Family

ID=58231605

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018546596A Pending JP2019507180A (ja) 2016-03-04 2017-03-03 がんに対する組合せ療法
JP2022027569A Active JP7417645B2 (ja) 2016-03-04 2022-02-25 がんに対する組合せ療法
JP2024000506A Active JP7785817B2 (ja) 2016-03-04 2024-01-05 がんに対する組合せ療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022027569A Active JP7417645B2 (ja) 2016-03-04 2022-02-25 がんに対する組合せ療法
JP2024000506A Active JP7785817B2 (ja) 2016-03-04 2024-01-05 がんに対する組合せ療法

Country Status (13)

Country Link
US (2) US20190343940A1 (enExample)
EP (2) EP3423087B1 (enExample)
JP (3) JP2019507180A (enExample)
DK (1) DK3423087T3 (enExample)
ES (1) ES2965009T3 (enExample)
FI (1) FI3423087T3 (enExample)
HR (1) HRP20240052T1 (enExample)
HU (1) HUE064857T2 (enExample)
LT (1) LT3423087T (enExample)
PL (1) PL3423087T3 (enExample)
PT (1) PT3423087T (enExample)
SI (1) SI3423087T1 (enExample)
WO (1) WO2017149150A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024510301A (ja) * 2021-03-17 2024-03-06 アイオー バイオテック エーピーエス がんのための併用療法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
HUE064857T2 (hu) * 2016-03-04 2024-04-28 Io Biotech Aps Kombinációs terápia a rák ellen
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
CN110546509A (zh) 2017-04-28 2019-12-06 戊瑞治疗有限公司 用cd80细胞外结构域多肽进行治疗的方法
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
WO2019102265A1 (en) * 2017-11-23 2019-05-31 Theraphage Inc. Peptide displaying bacteriophage nanoparticles and related compositions and methods
EP3713645A1 (en) * 2017-11-24 2020-09-30 IO Biotech APS Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc)
WO2019165077A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
AU2019361923B2 (en) 2018-10-15 2026-07-09 Five Prime Therapeutics, Inc. Combination therapy for cancer
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
AU2020224137B2 (en) 2019-02-22 2026-01-08 Five Prime Therapeutics, Inc. CD80 extracellular domain-Fc fusion proteins for treating PD-L1 negative tumors
MX2021013272A (es) 2019-05-03 2021-11-17 Five Prime Therapeutics Inc Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80.
KR102653960B1 (ko) * 2020-07-23 2024-04-03 의료법인 성광의료재단 암 치료를 위한 면역체크포인트 억제제의 병용 요법
BR112023017582A2 (pt) 2021-03-05 2023-12-05 Univ Basel Composições para o tratamento de doenças ou condições associadas ao ebv
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
CN117642432A (zh) * 2021-05-17 2024-03-01 威斯康星校友研究基金会 用于诱导免疫耐受的合成蛋白
EP4479085A1 (en) * 2022-02-18 2024-12-25 ModernaTX, Inc. Mrnas encoding checkpoint cancer vaccines and uses thereof
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2026008017A1 (en) * 2024-07-03 2026-01-08 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055111A1 (en) * 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
JP2014534202A (ja) * 2011-10-17 2014-12-18 ヘルレフ ホスピタルＨｅｒｌｅｖ Ｈｏｓｐｉｔａｌ Ｐｄ−ｌ１に基づく免疫療法
WO2015119944A1 (en) * 2014-02-04 2015-08-13 Incyte Corporation Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
DK2280721T3 (da) * 2008-04-17 2018-01-29 Io Biotech Aps Indoleamin-2, 3-dioxygenasebaseret immunterapi
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
ES2715018T3 (es) * 2014-05-30 2019-05-31 Ventana Med Syst Inc Ensayo múltiple para puntuar mejor los tejidos tumorales teñidos para PD-L1
HUE064857T2 (hu) * 2016-03-04 2024-04-28 Io Biotech Aps Kombinációs terápia a rák ellen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055111A1 (en) * 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
JP2014534202A (ja) * 2011-10-17 2014-12-18 ヘルレフ ホスピタルＨｅｒｌｅｖ Ｈｏｓｐｉｔａｌ Ｐｄ−ｌ１に基づく免疫療法
WO2015119944A1 (en) * 2014-02-04 2015-08-13 Incyte Corporation Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024510301A (ja) * 2021-03-17 2024-03-06 アイオー バイオテック エーピーエス がんのための併用療法

Also Published As

Publication number Publication date
LT3423087T (lt) 2024-01-25
US20190343940A1 (en) 2019-11-14
EP3423087A1 (en) 2019-01-09
PT3423087T (pt) 2023-12-28
ES2965009T3 (es) 2024-04-10
HRP20240052T1 (hr) 2024-03-29
PL3423087T3 (pl) 2024-05-20
FI3423087T3 (fi) 2023-12-15
WO2017149150A1 (en) 2017-09-08
JP2024045180A (ja) 2024-04-02
JP7417645B2 (ja) 2024-01-18
EP3423087B1 (en) 2023-11-15
HUE064857T2 (hu) 2024-04-28
EP4316517A2 (en) 2024-02-07
US20220257741A1 (en) 2022-08-18
DK3423087T3 (da) 2023-12-18
SI3423087T1 (sl) 2024-03-29
EP4316517A3 (en) 2024-05-29
JP7785817B2 (ja) 2025-12-15
JP2022068348A (ja) 2022-05-09

Similar Documents

Publication Publication Date Title
JP7417645B2 (ja) がんに対する組合せ療法
US12331097B2 (en) T cell receptor constructs and uses thereof
Sommershof et al. Chronic stress suppresses anti-tumor TCD8+ responses and tumor regression following cancer immunotherapy in a mouse model of melanoma
Kitagawa et al. Preclinical development of a WT1 oral cancer vaccine using a bacterial vector to treat castration-resistant prostate cancer
WO2005002621A2 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
JP2005523277A (ja) 癌の治療
JP2014534202A (ja) Ｐｄ−ｌ１に基づく免疫療法
JP2022027785A (ja) Ａｄｔとアンドロゲン受容体ワクチンとの組合せ療法
KR20240042414A (ko) 흑색종의 치료용 조성물 및 방법
CN117529551A (zh) 表达嵌合抗原受体的病毒特异性免疫细胞
Ishii et al. A combination of check-point blockade and α-galactosylceramide elicits long-lasting suppressive effects on murine hepatoma cell growth in vivo
JP6654207B2 (ja) 短鎖ペプチド抗腫瘍ワクチンを用いて早期のｔメモリー応答を誘発する方法。
WO2021077175A1 (en) Adoptive immunotherapy
JP2021504336A (ja) 抗体依存性細胞媒介性細胞傷害（ａｄｃｃ）の強化
HK40106688A (en) Combination therapy against cancer
EP2661622A1 (en) Bystander immune suppression as a predictor for response to a vaccine
KR20200093005A (ko) 암의 향상된 치료
CA2990893C (fr) Peptides immunogenes de preprocalcitonine
US20240307516A1 (en) Combination therapy for cancer
JP2026512959A (ja) 抗ｐｄ－１抗体又は抗ｐｄ－ｌ１抗体を用いたがん治療法
JP2024536152A (ja) サバイビンおよびｍａｇｅ－ａ９二重標的化免疫療法
Sultan The Role of Signal 3 Cytokines in Enhancing the Antitumor Effects of Peptide-Based Vaccines
EA041118B1 (ru) Способ индукции раннего ответа т-клеток памяти противоопухолевой вакциной из коротких пептидов

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211026